ALK and non-small cell lung carcinoma: MET amplification bypasses ROS1 inhibition in NSCLC; NTRK1 solvent‐front mutations (G595R/G667C) compromise TRK inhibitor efficacy, and ALK gatekeeper mutations drive relapse in IMTs—highlighting the imperative for next‐generation inhibitors (e.g., cabozantinib, repotrectinib).